Skip to main content
National Donor Day: How To Be the Match With Richa Thakur, MD, and Will Smith
Keira Smith
Expert Analysis
Oncology Data Advisor® · National Donor Day: How To Be the Match With Richa Thakur, MD, and Will Smith On February 14, Oncology Data Advisor is celebrating National Donor Day and recognizing the contributions of individuals who have given organ and tissue donations for patients in need. In this interview, Fellows Forum member Dr. Richa Thakur has a conversation with Will Smith, a High School History Teacher, who gave an anonymous stem cell donation through Be the Match (the National Marrow Donor Program, NMDP) in 2015.  
Gallbladder and Bile Duct Cancer Awareness Month: Improving Screening and Treatment Options With Waqas Haque, MD, MPH, and Matthew Hadfield, DO
Keira Smith
Expert Analysis
Oncology Data Advisor® · Gallbladder and Bile Duct Cancer Awareness Month: Improving Screening and Treatment Options In honor of Gallbladder and Bile Duct Cancer Awareness Month this February, Fellows Forum members Dr. Waqas Haque and Dr. Matthew Hadfield sat down for a discussion on the challenges in diagnosis of gallbladder and bile duct cancers and the importance of genetic sequencing for making targeted treatments available for patients.  
Investigating Odronextamab for R/R FL and DLBCL in the ELM-2 Study With Sabarish Ayyappan, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Investigating Odronextamab for R/R FL and DLBCL in the ELM-2 Study: Sabarish Ayyappan, MD At the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Sabarish Ayyappan, MD, the Director of Hematological Malignancies at the City of Hope Cancer Center, to discuss the ELM-2 s...
Utilizing ctDNA to Assess Survival With Odronextamab for FL and DLBCL With Jon Arnason, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Utilizing ctDNA to Assess Survival With Odronextamab for FL and DLBCL: Jon Arnason, MD At the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Jon Arnason, MD, a Lymphoma Clinical Trial Specialist at Beth Israel Deaconess Medical Center, to discuss his abstract and pre...
Guiding Dietary Choices During Multiple Myeloma Treatment With Richa Parikh, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Guiding Dietary Choices During Multiple Myeloma Treatment: Richa Parikh, MD In this interview from the 2023 American Society of Hematology Annual Meeting, Richa Parikh, MD, a third-year Hematology/Oncology Fellow at Karmanos Cancer Institute, discusses her team's study investigating the role of diet in multiple myeloma and how its findings can be used to help guide dietary decisions for patients.  
Exploring Acalabrutinib Plus or Minus Obinutuzumab for CLL in the ELEVATE-TN Study With Jeff Sharman, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Exploring Acalabrutinib ± Obinutuzumab for CLL in the ELEVATE-TN Study: Jeff Sharman, MD Recently, at the American Society of Hematology (ASH) Annual Meeting, Dr. Jeff P. Sharman, the Medical Director of Hematology Research for Sarah Cannon Research Institute and the US Oncology Network, presented the long...
Improving End-of-Life Care for Patients With Acute Myeloid Leukemia Receiving Non-Curative Therapy: Richa Thakur, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Improving End-of-Life Care for Patients With AML Receiving Non-Curative Therapy: Richa Thakur, MD In this interview from the American Society of Hematology (ASH) Annual Meeting, Dr. Richa Thakur, OncData Fellows Forum member and Hematology/Oncology Fellow at Northwell Health, discusses her poster presentation on ...
Improving Quality of Life in Multiple Myeloma Through Bortezomib Dose Reduction With Rahul Banerjee, MD, FACP, and Gurbakhash Kaur, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Improving QOL in Multiple Myeloma With Bortezomib Dose Reduction: Rahul Banerjee and Gurbakhash Kaur At the 2023 American Society of Hematology (ASH) Annual Meeting, Dr. Rahul Banerjee, Editor in Chief of Oncology Data Advisor, sat down with Dr. Gurbakhash Kaur, an Assistant Professor of Medicine at the University of Texas (UT) Southwestern Medical Center, to discuss their abstract about real-world dosing and prescribing patterns of bortezomib in newly diagnosed multiple myeloma. Dr. Banerjee and Dr. Kaur debate the pros and cons of once- versus twice-weekly dosing of bortezomib, its impact on tolerability and outcomes, and changes in trial design that are needed to make once-weekly dosing a new standard in clinical practice.  
Investigating Therapies Targeting Cardiovascular Health in MDS With Diego Adrianzen Herrera, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Investigating Therapies Targeting Cardiovascular Health in MDS: Diego Adrianzen Herrera, MD In this interview from the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor speaks with Dr. Diego Adrianzen Herrera, a Malignant Hematologist at the University of Vermont Medical Center, about his study investigating the impact of hypomethylating agents on cardiovascular disease risk for patients with myelodysplastic syndromes (MDS). Dr. Adrianzen Herrera explains the study's results and how they can be used to design future research around treatments targeting cardiovascular health in MDS.  
Investigating Talquetamab Plus Pomalidomide in the MonumenTAL-2 Study With Jeffrey Matous, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Investigating Talquetamab + Pomalidomide in the MonumenTAL-2 Study: Jeffrey Matous, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Jeffrey Matous, MD, a Member of the Colorado Blood Cancer Institute in Denver, Colorado, presented his team's research and results of the MonumenTAL-2 trial...
Insights from the State of AI Precision Oncology Conference
Waqas Haque, MD, MPH
Expert Analysis
By Waqas Haque, MD, MPH In a virtual seminar held on December 12 of last year, the State of AI Precision Oncology brought together a group of scientists and oncologists to delve into the transformative impact of artificial intelligence (AI) in oncology. Dr. Doug Flora, the Executive Medical Director of Oncology Services at St. Elizabeth Healthcare ...
A Mobile App to Address Sexual Dysfunction in HSCT Survivors: Areej El-Jawahri, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · A Mobile App to Address Sexual Dysfunction in HSCT Survivors: Areej El-Jawahri, MD After receiving hematopoietic stem cell transplantation (HSCT), many survivors experience issues with sexual dysfunction which can impact their quality of life. To address this challenge, Dr. Areej El-Jawahri, Director of the Bone Marrow Transplant Survivorship Program at Massachusetts General Hospital (MGH), and her team developed a multimodal mobile app as an intervention for sexual health concerns after transplant. After presenting this research at the 2023 American Society of Hematology (ASH) Annual Meeting, Dr. El-Jawahri sat down with Oncology Data Advisor to further explain the app's development and efficacy, as well as additional ways it can be used to improve quality of life for transplant survivors in the future.  
Coping With Psychological Distress Prior to Hematopoietic Cell Transplantation With Richard Newcomb, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Coping With Psychological Distress Prior to Hematopoietic Cell Transplantation: Richard Newcomb, MD Patients with hematologic malignancies undergoing hospitalization for hematopoietic cell transplantation experience significant psychological distress, and they cope in different ways. In this interview from the 2023 American Society of Hematology (ASH), Dr. Richard Newcomb, Instructor of Medicine at Harvard Medical School, discusses his presentation on coping mechanisms employed by patients who are preparing for transplantation and ways that health care providers can help support their patients during this time.  
Advancing Inclusion for Blood Donation Systems for Marginalized Groups With Warren Fingrut, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Advancing Inclusion for Blood Donation Systems for Marginalized Groups: Warren Fingrut, MD At the recent American Society of Hematology (ASH) Annual Meeting, Warren Fingrut, MD, a Transplant and Cell Therapy Physician at MD Anderson Cancer Center and Founder and Director of Stem Cell Club, a donor recruitment org...
Nurse Navigation and Financial Toxicity Programs to Reduce Socioeconomic Disparities in ALL With Greg Knight, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Nurse Navigation to Address Socioeconomic Disparities in ALL Treatment: Greg Knight, MD In this interview from the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor speaks with Greg Knight, MD, Clinical Assistant Professor of Medicine at Levine Cancer Institute, about his presentation on the impacts of nurse navigation and other supportive care services for reducing socioeconomic disparities in acute lymphoblastic leukemia (ALL) treatment. Additionally, Dr. Knight describes Levine Cancer Institute's Financial Toxicity Tumor Board, the first program of its kind, and shares advice for how other centers can implement similar interventions for mitigating socioeconomic disparities experienced by their patients.  
Maintaining Functioning and Quality of Life With Odronextamab for Follicular Lymphoma: Benoit Tessoulin, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Maintaining Functioning and QOL With Odronextamab for Follicular Lymphoma: Benoit Tessoulin, MD At the recent American Society of Hematology (ASH) Annual Meeting, Benoit Tessoulin, MD, PhD, Head of the Lymphoma Department at the Nantes University Hospital in France, sat down with Oncology Data Advisor to discuss ...
Investigating Hypomethylating Agents for Myelodysplastic Syndromes With Amer Zeidan, MBBS, MHS
Lyn Brook
Expert Analysis
Recently, at the American Society of Hematology (ASH) Annual Meeting, Amer Zeidan, MBBS, MHS, the Interim Chief of Hematologic Malignancies Division at the Yale Cancer Center, presented his abstract regarding an investigation of oral decitabine and cedazuridine versus intravenous/subcutaneous hypomethylating agents (HMA) for patients with myelodysp...
Predicting Immune-Related Adverse Events Through Machine Learning With OncoHost: Dr. Waqas Haque, Dr. Matthew Hadfield, and Dr. Ofer Sharon
Keira Smith
Expert Analysis
In this first episode of Oncology Data Advisor's new podcast series, "Exploring Artificial Intelligence in Cancer Care," Dr. Waqas Haque and Dr. Matthew Hadfield of the OncData Fellows Forum engage in a discussion with Dr. Ofer Sharon, CEO of OncoHost. Dr. Sharon provides an overview of the clinical need for increased knowledge of patients' probabilities of developing immune-related adverse events and explains the PROphet® platform, OncoHost's novel plasma-based, proteomic pattern analysis tool that uses a single blood sample to guide immunotherapy treatment decisions.  
Oncology Data Advisor at the American Society of Hematology (ASH) 2023 Annual Meeting
Keira Smith
Expert Analysis
At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. This podcast series features exclusive conversations on breaking data for novel therapies, technological...
New Lung Cancer Screening Guidelines With Brian Whang, MD, FACS
Lyn Brook
Expert Analysis
Recently, the American Cancer Society recommended new lung cancer screening guidelines to shift the focus from quitting smoking, to helping all individuals who have smoked despite quitting 20 to 30 years prior. In this interview, Dr. Brian Whang, Medical Director of Lung Cancer Screening for Hartford Healthcare, discusses these new guidelines, what...